中国科学院上海药物研究所黄永焯团队的一项最新研究研究显示，紫草素和JQ1共同递送通过抑制上皮-间质转化和血管生成模拟抑制三阴性乳腺癌进展和肺转移。这一研究成果发表在2025年7月14日出版的国际学术期刊《中国药理学报》上。

在这项研究中，该课题组人员提出了一种联合治疗策略，包括紫草素（SHK）和JQ1通过介孔多多巴胺皮克林乳剂（MPDA@PE）传递。该制剂通过诱导TNBC细胞凋亡，抑制TGF-β诱导的EMT和VM，显著抑制肿瘤生长和肺转移。

此外，MPDA@PE可掺入热敏水凝胶中，用于预防手术切除后TNBC复发和肺转移。这些发现强调了有效治疗TNBC的潜在治疗方法。

据介绍，三阴性乳腺癌（TNBC）极易发生肺转移，主要由上皮-间质转化（EMT）和血管源性模拟（VM）驱动。因此，抑制EMT和VM是一种很有前景的TNBC治疗策略。免疫抑制的肿瘤微环境是不良治疗结果的主要原因，M2型巨噬细胞分泌过量的TGF-β，促进EMT和VM。

附：英文原文

Title: Co-delivery of shikonin and JQ1 inhibits triple-negative breast tumor progression and lung metastasis through inhibition of epithelial-mesenchymal transition and vasculogenic mimicry

Author: Xu, Xing-yu, Kalambhe, Dipika Ramdas, Yu, Yue, Yu, Ling-xi, Gu, Zhi-wen, Jin, Xiao-ying, Wang, Hui-yuan, Huang, Yong-zhuo

Issue&Volume: 2025-07-14

Abstract: Triple-negative breast cancer (TNBC) is highly prone to lung metastasis, primarily driven by epithelial-mesenchymal transition (EMT) and vasculogenic mimicry (VM). Therefore, inhibiting EMT and VM represents a promising therapeutic strategy for TNBC. The immunosuppressive tumor microenvironment contributes substantially to poor treatment outcomes, with M2-type macrophages secreting excessive levels of TGF-β that promote both EMT and VM. In this study, we proposed a combination therapy strategy involving shikonin (SHK) and JQ1 delivered via a mesoporous polydopamine-based Pickering emulsion (termed MPDA@PE). This formulation significantly suppressed tumor growth and lung metastasis by inducing apoptosis in TNBC and inhibiting TGF-β-induced EMT and VM. Furthermore, MPDA@PE can be incorporated into a thermosensitive hydrogel for application in the prevention of TNBC recurrence and lung metastasis following surgical resection. These findings highlight a potential therapeutic approach for effective TNBC treatment.

DOI: 10.1038/s41401-025-01605-8

Source: https://www.nature.com/articles/s41401-025-01605-8